×
Efficacy Outcomes From 3 Clinical Trials of Edivoxetine as Adjunctive Treatment for Patients With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor Treatment PDF
$ 40.00
Efficacy Outcomes From 3 Clinical Trials of Edivoxetine as Adjunctive Treatment for Patients With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor Treatment PDF quantity
$ 40.00
×
The Diagnostic Challenge of Psychiatric Symptoms in Neurodegenerative Disease: Rates of and Risk Factors for Prior Psychiatric Diagnosis in Patients With Early Neurodegenerative Disease PDF
$ 40.00
The Diagnostic Challenge of Psychiatric Symptoms in Neurodegenerative Disease: Rates of and Risk Factors for Prior Psychiatric Diagnosis in Patients With Early Neurodegenerative Disease PDF quantity
$ 40.00
×
The Epidemiology of Social Anxiety Disorder in the United States: Results From the National Epidemiologic Survey on Alcohol and Related Conditions PDF
$ 40.00
The Epidemiology of Social Anxiety Disorder in the United States: Results From the National Epidemiologic Survey on Alcohol and Related Conditions PDF quantity
$ 40.00
×
Prevalence, Correlates, and Comorbidity of DSM-IV Antisocial Personality Syndromes and Alcohol and Specific Drug Use Disorders in the United States: Results From the National Epidemiologic Survey on Alcohol and Related Conditions PDF
$ 40.00
Prevalence, Correlates, and Comorbidity of DSM-IV Antisocial Personality Syndromes and Alcohol and Specific Drug Use Disorders in the United States: Results From the National Epidemiologic Survey on Alcohol and Related Conditions PDF quantity
$ 40.00
×
Dosing Quetiapine in Drug-Naive First-Episode Psychosis: A Controlled, Double-Blind, Randomized, Single-Center Study Investigating Efficacy, Tolerability, and Safety of 200 mg/day vs. 400 mg/day of Quetiapine Fumarate in 141 Patients Aged 15 to 25 Years PDF
$ 40.00
Dosing Quetiapine in Drug-Naive First-Episode Psychosis: A Controlled, Double-Blind, Randomized, Single-Center Study Investigating Efficacy, Tolerability, and Safety of 200 mg/day vs. 400 mg/day of Quetiapine Fumarate in 141 Patients Aged 15 to 25 Years PDF quantity
$ 40.00
Coupon: Apply coupon
Update cart
